Focus is on advancing cancer subtypes to predict disease progression and pursuing immune-biology related drug response biomarkers DURHAM, N.C., December 10, 2018 — GeneCentric Therapeutics, Inc. today announced that it has entered into a research collaboration with the University of North Carolina at Chapel Hill (UNC) to assess patient response to immunotherapeutic drugs such as […]

Company will develop Pancreatic Cancer Profiler based on technology to identify drug responders for therapeutic development DURHAM, N.C., September 24, 2018 — GeneCentric Therapeutics, Inc. today announced that the company has acquired an exclusive license from the University of North Carolina at Chapel Hill (UNC) to technology for subtyping Pancreatic Ductal Adenocarcinoma (PDAC). The company […]

GeneCentric Therapeutics, Inc. today announced the appointment of Michael V. Milburn, PhD, as Chief Scientific Officer (CSO).  Dr. Milburn, who joins GeneCentric from Metabolon, Inc. where he was CSO, has more than 25 years of R&D successful leadership experience in biotechnology companies and in a major pharmaceutical company. “Michael brings a broad range of expertise […]

GeneCentric Therapeutics’ CEO, Dr. Myla Lai-Goldman, will deliver a presentation at the Precision Medicine World Conference (PMWC) 2018 Duke University Program, September 24-25, entitled: “Delivering Greater Precision to Precision Medicine.” In an interview with PMWC ahead of the conference Dr. Lai-Goldman provides perspectives on novel cancer drug response biomarkers to enable more effective and efficient drug […]

Dr. Myla Lai-Goldman, co-founder and CEO of GeneCentric Therapeutics, will co-Chair a panel at the Next Generation Diagnostics (Dx) Summit 2018, August 20-24 in Washington, DC titled: “Paths to Universal Drug-Diagnostics Co-Development.” Next Generation Diagnostics Summit 2018, in its tenth year, includes over 1,000 international diagnostic professionals working in the field spanning cell- and cell-free […]

GeneCentric Therapeutics announced today that it will present the first data on the application of its proprietary Cancer Subtyping Platform (CSP®) to bladder cancer and its potential utility to provide drug response biomarkers for the disease. The gene expression subtyping data will be presented in a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL on June 2, 2018.

DURHAM, N.C., January 3, 2018 — GeneCentric Therapeutics, Inc. today announced a research collaboration to evaluate the potential of GeneCentric’s Cancer Subtype Platform (CSP®) to identify responders to G1 Therapeutics’ oral CDK4/6 inhibitor G1T38 for the treatment of non-small cell lung cancer (NSCLC).  As part of the research collaboration, GeneCentric will apply its lung cancer subtyping profilers (LSP™) in preclinical, patient-derived xenograft models to determine NSCLC subtype associations with G1T38 response, as well as examine potential drug response associations with specific genes.

Durham, NC, November 1 , 2017 – GeneCentric Therapeutics Founder and CEO, Dr. Myla-Lai Goldman, will be featured today on the radio show ”Radio In Vivo: Your Link to the Triangle Science Community!”, from 11:00am-12:00pm, ET, on WCOM – FM103.5, based in Carrboro, NC.

Durham, NC, October 26, 2017— GeneCentric Therapeutics announced today that it will present data on the potential of non-small cell lung cancer (NSCLC) biologic subtypes based on its Cancer Subtyping Platform (CSP®) to provide novel biomarkers for response to PARP inhibitors. The data will be presented at a poster session during the 2017 American Association for Cancer Research – National Cancer Institute – European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Therapeutics being held October 27-30, 2017 at the Philadelphia Convention Center, Philadelphia, PA.

GeneCentric Therapeutics, Inc., a precision medicine company dedicated to accelerating drug development by redefining the advanced classification of cancers, today announced the appointments of Walter M. Capone as Chief Business Officer and Ellen Lubman to the company’s Board of Directors.